Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase 2b/3 clinical trial for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart, which is in Phase 2 clinical trial; and MNPR-101, a humanized monoclonal antibody for the treatment of advanced cancers and severe COVID-19 that is in preclinical stage. The company has a collaboration Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19. It also has a collaboration agreement with the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in multiple types of cancer. Monopar Therapeutics Inc. was founded in 2014 and is headquartered in Wilmette, Illinois.
IPO Year: 2019
Exchange: NASDAQ
Website: monopartx.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
10/11/2024 | $50.00 | Buy | Rodman & Renshaw |
11/1/2021 | $9.00 | Buy | HC Wainwright & Co. |
Monopar Therapeutics Inc. has recently seen notable insider activity, with Chief Operating Officer Cittadine Andrew purchasing $25,574 worth of shares on June 21st, 2024. This purchase, comprising 32,508 units at $0.79, increased Cittadine's direct ownership by 21% to 186,132 units as reported in the SEC Form 4. When analyzing this transaction alongside other recent insider activities within the company, interesting patterns and trends start to emerge. Looking back, Cittadine Andrew has been consistently adding to his position in Monopar Therapeutics Inc. over the past few months, showcasing a strong conviction in the company's future prospects. On May 31st, Cittadine Andrew made a substan
4 - Monopar Therapeutics (0001645469) (Issuer)
4 - Monopar Therapeutics (0001645469) (Issuer)
4 - Monopar Therapeutics (0001645469) (Issuer)
4 - Monopar Therapeutics (0001645469) (Issuer)
4 - Monopar Therapeutics (0001645469) (Issuer)
WILMETTE, Ill., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the first patient ever dosed with MNPR-101-Lu. This novel therapeutic radiopharmaceutical combines MNPR-101, Monopar's antibody that selectively targets the urokinase plasminogen activator receptor (uPAR), with the therapeutic radioisotope lutetium-177. uPAR is involved in tumor growth and metastasis, and is found in some of the most aggressive, deadly cancers, including pancreatic, ovarian, triple negative breast, and colorectal cancers. The MNPR-101-Lu intraveno
WILMETTE, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced that Chandler Robinson, MD, Monopar's Chief Executive Officer, will participate in a fireside chat along with one-on-one meetings at the 36th Annual Piper Sandler Healthcare Conference. Presentation Details: Date: December 5, 2024Time: 10:30-10:55 am Eastern Time Location: Lotte New York Palace, NY, NY About Monopar Therapeutics Inc. Monopar Therapeutics is a clinical-stage biotechnology company with late-stage ALXN-1840 for Wilson disease, and radiopharma prog
In-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare DiseaseTwo Novel Radiopharma Clinical Trials now Active and Enrolling Patients with Advanced Solid Cancers WILMETTE, Ill., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced third quarter 2024 financial results and summarized recent developments. Recent Developments ALXN-1840 for Wilson disease – Late Stage On October 23, 2024, the Company entered into an exclusive license with Alexion, AstraZeneca Ra
WILMETTE, Ill., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR) ("Monopar Therapeutics" or the "Company"), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the closing of its previously announced best efforts public offering of shares of its common stock at a public offering price of $16.25 per share, for aggregate gross proceeds of approximately $19.2 million, before deducting the placement agent's fees and other offering expenses payable by the Company. Janus Henderson Investors, RA Capital Management, L.P. and other notable growth and life science investors participated
WILMETTE, Ill., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR) ("Monopar Therapeutics" or the "Company"), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the pricing of its best efforts public offering of shares of its common stock at a public offering price of $16.25 per share, for aggregate gross proceeds of approximately $19.2 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The offering is expected to close on October 30, 2024, subject to satisfaction of customary closing conditions. Janus Henderson Investors,
WILMETTE, Ill., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR) ("Monopar Therapeutics" or the "Company"), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced that it intends to offer to sell shares of its common stock in a best efforts public offering. All of the shares of common stock are to be sold by the Company. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Rodman & Renshaw LLC is acting as the exclusive placement agent for the offering. Mono
WILMETTE, Ill., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced that it has entered into an agreement with Alexion, AstraZeneca Rare Disease for an exclusive worldwide license to ALXN-1840 (bis-choline tetrathiomolybdate), a drug candidate for Wilson disease that Alexion has progressed through a Phase 3 clinical trial that met its primary endpoint. Monopar will be responsible for all future global development and commercialization activities. Chandler D. Robinson, MD, Co-Founder and Chief Executive Officer of Monopar previousl
WILMETTE, Ill., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, is presenting today data from the clinical and preclinical development of its novel first-in-class lead radiopharma program based on MNPR-101 at the European Association of Nuclear Medicine (EANM) 2024 Annual Congress held in Hamburg, Germany. MNPR-101-Lu radiation dosimetry analytics using human data from MNPR-101-Zr show a favorable organ safety profile at high Lu-177 therapeutic dose levels. The slides for Monopar's oral presentation can be found at the following link: https://www.monopart
WILMETTE, Ill., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced the filing of a provisional patent covering new therapeutic radiopharmaceuticals based on a family of linkers used to connect radioisotopes with targeting agents, including Monopar's uPAR targeting antibody MNPR-101. Highlights of the patent filing include: Composition of Matter: Claims cover a family of linkers, as well as Monopar's uPAR targeting agents linked with these along with therapeutic radioisotopesStability and Biodistribution: These proprietary new linkers have been crea
WILMETTE, Ill., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced that the Phase 1a clinical trial for its novel therapeutic radiopharmaceutical MNPR-101-Lu (MNPR-101 conjugated to lutetium-177) is now active and recruiting patients with advanced cancers. The Phase 1a trial is an open-label dose-escalation study of MNPR-101-Lu in patients with solid tumors. The first clinical trial site activated for the study is the Melbourne Theranostic Innovation Centre (MTIC) in Australia. To help identify those patients most likely to benefit from MNPR-101-L
8-K - Monopar Therapeutics (0001645469) (Filer)
S-3 - Monopar Therapeutics (0001645469) (Filer)
8-K - Monopar Therapeutics (0001645469) (Filer)
10-Q - Monopar Therapeutics (0001645469) (Filer)
8-K - Monopar Therapeutics (0001645469) (Filer)
424B5 - Monopar Therapeutics (0001645469) (Filer)
424B5 - Monopar Therapeutics (0001645469) (Filer)
8-K - Monopar Therapeutics (0001645469) (Filer)
8-K - Monopar Therapeutics (0001645469) (Filer)
8-K - Monopar Therapeutics (0001645469) (Filer)
SC 13G - Monopar Therapeutics (0001645469) (Subject)
SC 13G - Monopar Therapeutics (0001645469) (Subject)
SC 13G - Monopar Therapeutics (0001645469) (Subject)
SC 13G - Monopar Therapeutics (0001645469) (Subject)
SC 13G - Monopar Therapeutics (0001645469) (Subject)
4 - Monopar Therapeutics (0001645469) (Issuer)
4 - Monopar Therapeutics (0001645469) (Issuer)
4 - Monopar Therapeutics (0001645469) (Issuer)
4 - Monopar Therapeutics (0001645469) (Issuer)
3 - Monopar Therapeutics (0001645469) (Issuer)
4 - Monopar Therapeutics (0001645469) (Issuer)
4 - Monopar Therapeutics (0001645469) (Issuer)
4 - Monopar Therapeutics (0001645469) (Issuer)
4 - Monopar Therapeutics (0001645469) (Issuer)
4 - Monopar Therapeutics (0001645469) (Issuer)
WILMETTE, Ill., July 12, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the appointment of Octávio Costa, MD, as Chief Medical Officer. In this role, Dr. Costa will oversee global clinical development and regulatory affairs, and will provide strategic direction for Monopar's pipeline. Dr. Costa joins Monopar with over 30 years of experience overseeing clinical development, clinical operations, development strategy and global medical affairs. He has extensive Phase 1 through 4 clini
WILMETTE, Ill., June 01, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the appointment of Andrew Cittadine, MBA, as Chief Operating Officer. In this role, Mr. Cittadine will provide leadership and oversight of Monopar's global operations and business and development strategy. Mr. Cittadine is an experienced healthcare executive and serial entrepreneur with a successful track record of identifying, founding, and building healthcare businesses from concept to commercialization
WILMETTE, Ill., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the appointment of Laura Kelly as Director of Clinical Operations. Ms. Kelly will be responsible for managing Monopar’s clinical programs, including the recently launched Phase 2b/3 VOICE trial for the Company’s lead drug candidate Validive®. Ms. Kelly brings a wealth of clinical research experience, including oncology and the execution of Phase 1 through Phase 4 clinical trials, to the Monopar team. Prior to
Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced that its abstract titled "Evaluation of Anti-uPAR Antibody as a Radiopharmaceutical for Imaging and Treatment of Solid Tumors" has been accepted as a "Top-Rated Oral Presentation" within the Scientific Program of the European Association of Nuclear Medicine (EANM) 2024 Annual Congress to be held on October 19-23, 2024 in Hamburg, Germany.
The Dow Jones index closed higher by around 15 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Monopar Therapeutics The Trade: Monopar Therapeutics Inc. (NASDAQ:MNPR) Chief Operating Officer Andrew Cittadine bought a total of 32,508 shares at an average price of $0.79. To acquire these shares, it cost around $25,574. What's Happening: On
Monopar Therapeutics Inc. has recently seen notable insider activity, with Chief Operating Officer Cittadine Andrew purchasing $25,574 worth of shares on June 21st, 2024. This purchase, comprising 32,508 units at $0.79, increased Cittadine's direct ownership by 21% to 186,132 units as reported in the SEC Form 4. When analyzing this transaction alongside other recent insider activities within the company, interesting patterns and trends start to emerge. Looking back, Cittadine Andrew has been consistently adding to his position in Monopar Therapeutics Inc. over the past few months, showcasing a strong conviction in the company's future prospects. On May 31st, Cittadine Andrew made a substan
Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, is presenting today data from the preclinical development of its novel first-in-class lead radiopharma program MNPR-101-Zr at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Toronto, Canada. SNMMI is the premier educational, scientific, and research event in the radiopharma space. Monopar's poster presentation can be found at the following link: https://www.monopartx.com/pipeline/mnpr-101/snmmi-poster-june-2024.
Gainers Venus Concept (NASDAQ:VERO) shares increased by 135.2% to $1.38 during Friday's pre-market session. The market value of their outstanding shares is at $8.7 million. Adlai Nortye (NASDAQ:ANL) shares moved upwards by 56.64% to $6.72. The market value of their outstanding shares is at $247.9 million. BioCardia (NASDAQ:BCDA) shares moved upwards by 52.57% to $6.66. The market value of their outstanding shares is at $12.1 million. Geron (NASDAQ:GERN) stock rose 22.36% to $4.76. The market value of their outstanding shares is at $2.8 billion. Seelos Therapeutics (NASDAQ:SEEL) stock moved upwards by 14.66% to $1.29. The market value of their outstanding shares is at $3.3 million. Inda
The Dow Jones index closed higher by around 575 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Grove Collaborative Holdings The Trade: Grove Collaborative Holdings, Inc. (NYSE:GROV) President and CEO Jeffrey Michael Yurcisin bought a total of 17,100 shares at an average price of $1.63. To acquire these shares, it cost around $27,951. Wh
Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that after a career spanning more than 35 years, Monopar's Chief Financial Officer, Kim R. Tsuchimoto, will be retiring. Ms. Tsuchimoto will be transitioning over the next month, with her last day being on June 30, 2024. Ms. Tsuchimoto will remain as a member of Monopar's Board of Directors.Monopar has been working over the past 6-plus months on a consulting basis with Karthik Radhakrishnan. Effective July 1, 2024, Mr. Radhakrishnan will be appointed Monopar's Chief Financial Officer, Principal Accounting Officer, and Principal
HC Wainwright & Co. analyst Sean Lee reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintains $2 price target.
Gainers Sensus Healthcare (NASDAQ:SRTS) shares increased by 33.3% to $5.08 during Thursday's after-market session. The market value of their outstanding shares is at $83.2 million. As per the news, the Q1 earnings report came out today. TELA Bio (NASDAQ:TELA) shares moved upwards by 13.36% to $5.6. The company's market cap stands at $138.0 million. As per the press release, Q1 earnings came out today. CareDx (NASDAQ:CDNA) stock increased by 13.01% to $12.5. The company's market cap stands at $650.1 million. The company's, Q1 earnings came out today. Natera (NASDAQ:NTRA) stock moved upwards by 12.42% to $107.5. The market value of their outstanding shares is at $13.1 billion. As per the p
Rodman & Renshaw initiated coverage of Monopar Therapeutics with a rating of Buy and set a new price target of $50.00
HC Wainwright & Co. initiated coverage of Monopar Therapeutics with a rating of Buy and set a new price target of $9.00
ROTH Capital initiated coverage of Monopar Therapeutics with a rating of Buy and set a new price target of $49.00